VXRT - Vaxart: Too Early To Dismiss This COVID-19 Vaccine Opportunity
Investment Thesis
The stock prices of biotechs developing vaccine solutions for COVID-19 have declined markedly over the past couple of weeks, despite the need for a coronavirus cure being greater than ever.
Performance of selected biotech vaccine/adjuvant developers Vaxart, Moderna, Novavax, and Invio, past 6 months. Source: TradingView.
Although many COVID-19 vaccine or adjuvant developers still trade hundreds of percentage points above their pre-pandemic levels, as we can see above, it appears the market has become desensitised to the steady stream of news flow relating to manufacturing and distribution deals, early-stage trial data and